var data={"title":"Fludeoxyglucose F-18: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fludeoxyglucose F-18: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/147121?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fludeoxyglucose-f-18-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fludeoxyglucose F-18: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13172595\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Radiopharmaceutical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13172699\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Positron emission tomography (PET) imaging (oncology, cardiology, and neurology settings):</b> IV (based on 70 kg patient): 5 to 10 mCi (185 to 370 MBq)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13172698\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Positron emission tomography (PET) imaging</b> <b>(neurology setting):</b> IV: 2.6 mCi (96.2 MBq); optimal dose adjustment on body size or weight has not been determined</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15881450\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15881451\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23613299\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, for injection [preservative free]: 20-300 mCi/mL (20 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20217880\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Administer as an IV injection. Initiate imaging within 40 minutes of administration. Encourage patients to adequately hydrate for 4 hours prior to administration. Instruct patients in oncology or neurology settings to fast 4 to 6 hours prior to administration; also, consider medical therapy or laboratory testing to ensure at least 2 days of normoglycemia prior to administration. In the cardiology setting, administering 50 to 75 g of glucose-containing foods or liquids prior to administration will facilitate localization of cardiac ischemia. To minimize bladder exposure, patients should void when imaging is complete and as often as possible thereafter for at least 1 hour.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Radiopharmaceutical; use appropriate precautions for handling and disposal. Waterproof gloves should be worn and effective shielding should be used during handling and administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13172458\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Positron emission tomography (PET) imaging:</b> Fluorinated deoxyglucose used in conjunction with positron emission tomography (PET) imaging for assessment of abnormal glucose metabolism to assist in evaluating malignancy in patients with known or suspected abnormalities found by other testing modalities or in patients with diagnosis of cancer; in conjunction with myocardial perfusion imaging to identify left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction; to detect areas in the brain with abnormal glucose metabolism linked with foci of epileptic seizures</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13255249\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13172579\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Endocrine &amp; metabolic: Hyper-/hypoglycemia (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Transient hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Transient alkaline phosphatase increased</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25593614\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to fludeoxyglucose or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13172507\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes mellitus: In patients in the oncology or neurology setting with inadequately regulated blood glucose levels, suboptimal imaging may occur; consider medical therapy and laboratory testing to assure 2 days of normal blood glucose prior to administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special handling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patient information: Instruct patients in oncology or neurology settings to fast 4 to 6 hours prior to administration. In the cardiology setting, intake of 50 to 75 grams of glucose-containing foods or liquids will facilitate localization of cardiac ischemia. Encourage patients to adequately hydrate for 4 hours prior to administration; patients should void when imaging is complete and as often as possible thereafter for at least 1 hour to minimize bladder exposure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13172516\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13172517\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Alternative tests should be considered in pregnant women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20688336\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;\">It is not known if fludeoxyglucose F 18 is present in breast milk. Consider alternative diagnostic tests in women who are breastfeeding. Use alternatives to breastfeeding (eg, stored breast milk or infant formula) for at least 10 half-lives of radioactive decay, if fludeoxyglucose F 18 injection is administered to a nursing woman.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26529878\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>(18F) FDG-FR 300 (LV);</li>\n      <li>Barnascan (ES);</li>\n      <li>Duchembio FDG (KR);</li>\n      <li>Efdege (HR);</li>\n      <li>EFDEGE (NL);</li>\n      <li>Ertracer (IE);</li>\n      <li>Farna-FDG (ES);</li>\n      <li>FDG (SE);</li>\n      <li>FDG-FR (EE);</li>\n      <li>FDG-RMC (HR);</li>\n      <li>FDGCADPET (ES);</li>\n      <li>FDGEN (AU);</li>\n      <li>FDGscan (JP);</li>\n      <li>FID-F (RO);</li>\n      <li>Flu Swan (CH);</li>\n      <li>Flucis (ES, FR);</li>\n      <li>Fu Tang Pai Te (CN);</li>\n      <li>Gluco-PET (HU);</li>\n      <li>Glucoscan (FR);</li>\n      <li>Glucotep (FR);</li>\n      <li>Glucotrace (NL);</li>\n      <li>Gluscan (CH);</li>\n      <li>Metatrace FDG (KR);</li>\n      <li>Pozitronscan - FDG (HU);</li>\n      <li>Steripet (CZ, EE, NL, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Cyclodx (fludeoxyglucose F 18) [product monograph]. Sherbrooke, Qu&eacute;bec, Canada: Centre int&eacute;gr&eacute; universitaire de sant&eacute; et de services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fludeoxyglucose F 18 (fludeoxyglucose f-18 injection) [prescribing information]. Dulles, VA: Zevacor Pharma, Inc.; August 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16795 Version 53.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F13172595\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F13172699\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F13172698\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15881450\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15881451\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F23613299\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F20217880\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F13172458\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F13255249\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F13172579\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F25593614\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F13172507\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F13172516\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13172517\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20688336\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F26529878\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/16795|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fludeoxyglucose-f-18-patient-drug-information\" class=\"drug drug_patient\">Fludeoxyglucose F-18: Patient drug information</a></li></ul></div></div>","javascript":null}